Quantcast
Last updated on April 21, 2014 at 12:45 EDT

Japanese Heart Valve Device Market Growth Will Spike With The Launch of Transcatheter Heart Valves

May 30, 2013

Edwards Lifesciences Will Once Again Be First To Market, According to Millennium Research Group

TORONTO, May 30, 2013 /PRNewswire/ — According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, transcatheter aortic valve replacement (TAVR) devices will launch in Japan in 2013, spurring accelerating growth in the market. Unlike conventional heart valve devices, TAVR devices are placed percutaneously, minimizing the trauma to the patient. This allows heart valve replacements to be performed in candidates who were otherwise ineligible for surgical options due to comorbidities or other factors. As a result, the adoption of TAVR devices will be rapid; these products will be used in about 30 percent of total heart valve replacements performed in Japan by 2021.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36799LOGO )

“After the US and Europe, Japan represents the next frontier for TAVR devices,” said MRG Senior Analyst Ian Swanson. “Edwards Lifesciences continues to be first-to-market with these products, providing the company with an extremely powerful competitive advantage. Although Medtronic is not too far behind, Edwards Lifesciences holds a particular advantage in Japan where it will offer its smallest-sized version of its SAPIEN XT TAVR device, which is ideal for Japanese patients.”

Although the focus for the next few years will be on transcatheter devices, the conventional heart valve market nonetheless remains large and lucrative. The sizable over-65 demographic combined with rising rates of diabetes and obesity in Japan has created a growing patient pool for heart valve treatments, and many eligible patients will continue to undergo conventional surgical replacement or repair, especially while TAVR remains a relatively new procedure.

The market will, however, be somewhat hindered by lagging economic recovery from the earthquake and tsunami of 2011 and the global economic downturn; this will hinder hospital budgets, particularly in the next few years. While this will impede growth in the surgical heart valve device markets, price erosion will be more than offset by the rapid adoption of premium-priced TAVR devices, resulting in the Japanese heart valve device market growing at a strong pace overall.

Millennium Research Group’s Japanese Markets for Heart Valve Devices 2013 report includes unit, procedure, average selling price and revenue information, along with market drivers and limiters and a competitive landscape for heart valve replacement and repair devices in Japan.

About Millennium Research Group
Millennium Research Group (www.MRG.net), a Decision Resources Group company (www.DecisionResourcesGroup.com), is the global authority on medical technology market intelligence and the leading provider of strategic information to the healthcare sector. The company provides specialized industry expertise through multiclient market research, ongoing Marketrack(TM) projects, customer loyalty tracking, facility-level procedure forecasting, and customized solutions.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information, and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

    Christopher Comfort      Alex Jablokow
    Decision Resources Group Millennium Research Group
    781-993-2597             617-599-8613
    ccomfort@dresources.com  ajablokow@mrg.net

SOURCE Millennium Research Group


Source: PR Newswire